Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Nucleic Acids and Circulating Rare Cells: Liquid Biopsy for Early Cancer Detection

George Calin's Biography



George Calin, Professor and The Alan M. Gewirtz Leukemia & Lymphoma Society Scholar, University of Texas MD Anderson Cancer Center

George Adrian Calin received both his M.D. and Ph.D. degrees at Carol Davila University of Medicine in Bucharest, Romania. After working cytogenetics as undergraduate student with Dr. Dragos Stefanescu in Bucharest, he completed a cancer genomics training in Dr. Massimo Negrini’s laboratory at University of Ferrara, Italy. In 2000 he became a postdoctoral fellow at Kimmel Cancer Center in Philadelphia, PA, and while working in Dr. Carlo Croce laboratory Dr. Calin was the first to discover the link between human cancers and microRNAs, a finding considered as a milestone in microRNA research history. He has now developed starting from July 2007 an independent research group at the M. D. Anderson Cancer Center in Houston and produced a new advance by linking new classes of non-coding RNAs to cancer. He is presently a Professor in Experimental Therapeutics at MDACC and studies the roles of microRNAs and other non-coding RNAs in cancer initiation and progression and in immune disorders, as well as the mechanisms of cancer predisposition linked to non-codingRNAs. Furthermore, he explores the roles of body fluids miRNAs as potential hormones and biomarkers, as well as new RNA therapeutic options for cancer patients.

George Calin Image

About Noam Chomsky, DNA Motifs, Non-coding RNAs and Cancer Patients

Thursday, 29 March 2018 at 12:00

Add to Calendar ▼2018-03-29 12:00:002018-03-29 13:00:00Europe/LondonAbout Noam Chomsky, DNA Motifs, Non-coding RNAs and Cancer PatientsSELECTBIOenquiries@selectbiosciences.com

The newly discovered differential expression in numerous tissues, key cellular processes and multiple diseases for several families of long and short non-codingRNAs (ncRNAs, RNAs that do not codify for proteins but for RNAs with regulatory functions), including the already famous class of microRNAs (miRNAs) strongly suggest that the scientific and medical communities have significantly underestimated the spectrum of ncRNAs whose altered expression has significant consequences in diseases. MicroRNA and other short or long non-codingRNAs alterations are involved in the initiation, progression and metastases of human cancer. The main molecular alterations are represented by variations in gene expression, usually mild and with consequences for a vast number of target protein coding genes. The causes of the widespread differential expression of non-codingRNAs in malignant compared with normal cells can be explained by the location of these genes in cancer-associated genomic regions, by epigenetic mechanisms and by alterations in the processing machinery. MicroRNA and other short or long non-codingRNAs expression profiling of human tumors has identified signatures associated with diagnosis, staging, progression, prognosis and response to treatment. In addition, profiling has been exploited to identify non-codingRNAs that may represent downstream targets of activated oncogenic pathways or that are targeting protein coding genes involved in cancer. Recent studies proved that miRNAs and non-coding ultraconserved genes are main candidates for the elusive class of cancer predisposing genes and that other types of non-codingRNAs participate in the genetic puzzle giving rise to the malignant phenotype. Last, but not least, the shown expression correlations of these new ncRNAs with cancer metastatic potential and overall survival rates suggest that at least some member of these novel classes of molecules could potentially find use as biomarkers or novel therapeutics in cancers and other diseases.


Add to Calendar ▼2018-03-28 00:00:002018-03-29 00:00:00Europe/LondonCirculating Nucleic Acids and Circulating Rare Cells: Liquid Biopsy for Early Cancer Detection SELECTBIOenquiries@selectbiosciences.com